2021-01-04,"b'@marko1332 @pawcio2009 Was surprised to see $FGEN not making it to the list, glad that $HARP did'"
2021-01-03,"b'$FGEN $37.09 -0.88  -2.32%Roxadustat Anaemia in Chronic Kidney Disease PDUFA date extended by three months to March 20, 2021.\n$AZN $49.99 -0.19  -0.38%Roxadustat Anaemia in Chronic Kidney Disease PDUFA date extended by three months to March 20, 2021.'"
2021-01-03,b'RT @marko1332: @pawcio2009 Aside from $FGEN what other stocks didn\xe2\x80\x99t make the list this year from last year'
2021-01-03,b'@pawcio2009 Aside from $FGEN what other stocks didn\xe2\x80\x99t make the list this year from last year'
2021-01-03,b'@DynamicMec Have pos in most bio fan favs: $dmtk $iova $asnd $bpmc $crsp $exas $fate $gh $kod $nvcr $stok &amp; while these can go higher- many have run too far for M&amp;A to make strategic + $ sense! The ones that haven\xe2\x80\x99t ran yet: $kala $gthx $kpti $evfm $chma $zgnx $fgen $onct $tril $espr $dtil'
2021-01-03,b'Calls held:\n1/8\n$RIOT $20\n1/15\n$AMZN $3500 $ARCT 50\n$BPY 20 $CNET 2 $DIS 190 \n$FGEN 60 $GSKY 5 $MJ 20\n$MPLN 12.5 $PAYS 7.5\n$PRTY 7.5 $SONO 30\n$SPOT 350 $TDOC 250\n$TIF 135 $TSLA 700\n$WKHS 20 $WKHS 30\n1/22\n$ZM $410\n(1/3)'
2021-01-03,b'$FGEN Wake me up when we are green .. lol.  \xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd -2.32 % change recently https://t.co/JpCVW85Kr1'
2021-01-03,b'$SNRG to get massive exposure following next weeks scheduled segment on CNBC Squawk Box\nhttps://t.co/fK8PPZ6hwp\n\n$ATKR $SERV $EVH $SRUP $CYD $HPP $UTHR $APPS $APHQF $FGEN $IRBL $EPXY $TONR'
2021-01-02,b'$FGEN Lets see how this turns out -2.32 % https://t.co/JpCVW85Kr1'
2021-01-02,"b""$FGEN's 10-day Moving Average crossed below its 50-day Moving Average on December 29, 2020. View odds for this and other indicators: https://t.co/68FBPB26Hw #FibroGen #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/8zD0J11N1E"""
2021-01-02,"b""$FGEN Would say I'm surprised, but I'm not. Will check ER. Might dabble again. Maybe.  -2.32 % change recently https://t.co/8DpmJxbXgv"""
2021-01-02,b'#Timestamped tweet when I first got in $CELH\n\nTech stocks can give great returns without binary risks like you find in biotechs.  \n$NTEC $ACOR $XAIR $FGEN $KPTI https://t.co/T8xkRehMsg'
2021-01-01,"b""$FGEN's 10-day Moving Average crossed below its 50-day Moving Average on December 29, 2020. View odds for this and other indicators: https://t.co/T2EdpNU1TN #FibroGen #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/3sGa1rDGux"""
2021-01-01,b'$FGEN  major movements -2.24 % change recently https://t.co/JpCVW85Kr1'
2021-01-01,b'RT @bigpharmaguy: What are key remaining catalysts before end of year? \n$ARVN 110 dose escalation follow up. \n$APRE Ph3 readout \n$SIOX GM1\xe2\x80\xa6'
2021-01-01,b'RT @bigpharmaguy: What are key remaining catalysts before end of year? \n$ARVN 110 dose escalation follow up. \n$APRE Ph3 readout \n$SIOX GM1\xe2\x80\xa6'
2020-12-31,"b'Large Print $FGEN Size: 128361 Price: 37.09 Time: 1600 Amount: $4,760,909.49'"
2020-12-31,b'@Pharmdca thoughts on $FGEN ?'
2020-12-31,"b""$FGEN - RSI is moving bottom to top; expecting bounce back; selling pressure is mini when xbi is very weak; Nice support now. I'm in here. https://t.co/HPcKCkD2ii"""
2020-12-31,b'@Pharmdca Have not heard from you or BTGpremium on $fgen of late . Still a believer?'
2020-12-31,"b'RT @Frankie1x2: @JakeArman6 @oRx_93 @tuduylinh Cant see your problem. $Fgen has robust Roxa data, even if you include Pyrenees into the dat\xe2\x80\xa6'"
2020-12-31,"b'@JakeArman6 @oRx_93 @tuduylinh Cant see your problem. $Fgen has robust Roxa data, even if you include Pyrenees into the data set. See Fgen response to CP. \nIf you have problems with HIF data please get in touch with Akebia management.  They have a lot of problems.'"
2020-12-31,b'$FGEN new insider selling: 6001 shares. https://t.co/QM2K0K4XwT'
2020-12-31,b'Calls held:\n1/8\n$SPY $378\n1/15\n$AMZN $3500 $ARCT 50\n$BPY 20 $CNET 2 $DIS 190 \n$FGEN 60 $GSKY 5 $MJ 20\n$MPLN 12.5 $PAYS 7.5\n$PRTY 7.5 $SONO 30\n$SPOT 350 $TDOC 250\n$TIF 135 $TSLA 700\n$WKHS 20 $WKHS 30\n1/22\n$ZM 410\n(1/3)'
2020-12-30,"b'$FGEN FibroGen, Inc SEC Filing: Form 4 https://t.co/bG3BiIjrod'"
2020-12-30,"b'Kalevi Kurkijarvi,  of FIBROGEN INC - $FGEN sold 6001 shares to now own a total of 33100, anomalous of their normal trading pattern.\n\nhttps://t.co/Lj60R6QKal'"
2020-12-30,"b'@SurrogateCap @wshao8 @biostockguru Lol- if it breaks 14 I\xe2\x80\x99ll be buying 5k share blocks every .10:) Is $kpti really gonna fall massively if it breaks 14? A couple points of downside, at most imo, for 15+ on upside- these are the setups we search for- r/r favors long! Same with $kala $gthx $chma $fgen &amp; others!'"
2020-12-30,b'@SelfThink4 When $ions has a mv of $20 billion+ they might entertain an offer of $35 to 40 billion. With a little luck the former could happen in 2021. $gbt $crsp $auph $tril $tgtx $gild $biib $edit $ntla $dnli $alny $eigr $drrx $fbiox $fgen $tak $mrna $ibb'
2020-12-30,"b""@farcap @forestfromthe__ @brendan_49 Vada was approved in Japan before its dreadful US data was even released. Japan's not really a good predictor for either the FDA or the US or ROW market.  Based on the data, no one should take Vada when Roxa is available. $AKBA $FGEN"""
2020-12-30,"b'RT @brendan_49: What is the combined valuation of the HIF-PH for CKD anemia space? $FGEN $3.5b cap, lets attribute $1b to cash + pamrev, so\xe2\x80\xa6'"
2020-12-30,"b""RT @chrisintroy: @JamesEKrause Thanks Jim. I realize roxa wouldn't be the drug for that indication. I was being lazy\xf0\x9f\x98\xa9, hoping that someone\xe2\x80\xa6"""
2020-12-30,"b""@JamesEKrause Thanks Jim. I realize roxa wouldn't be the drug for that indication. I was being lazy\xf0\x9f\x98\xa9, hoping that someone familiar with $FGEN IP would know whether they had any around HIF in #AlzheimersDisease. I've certainly never heard of it and have no idea what it takes to drug the brain."""
2020-12-30,"b'RT @JamesEKrause: @chrisintroy Roxadustat has extremely limited CNS exposure if any, probably only via the breeched blood-brain barrier at\xe2\x80\xa6'"
2020-12-30,"b'@chrisintroy Roxadustat has extremely limited CNS exposure if any, probably only via the breeched blood-brain barrier at circumventricular organs, such as area postrema. I have not heard of $FGEN mentioning #AlzheimersDisease.'"
2020-12-30,"b""$FGEN Does anyone know if they've ever talked about AD? There are a few pubmed abstracts as well.\n\nhttps://t.co/YNWetIWq5M"""
2020-12-30,"b""@john_bresnahan @brendan_49 'interesting pickup for someone', indeed if interesting = complicated, inasmuch as that someone (other than AZN) must agree to go to the alter with $FGEN partner(s). That July 2019 article on ESAs, int and thanks, wonder if such numbers borne out, or will be?"""
2020-12-30,"b""@forestfromthe__ @brendan_49 Agreeing with Rob F. It's hard to see $AKBA selling any Vad at all, even if it does somehow make it to market. And, at this stage, we don't know that Dap isn't just as bad. Roxa will dominate. $FGEN."""
2020-12-30,"b'RT @brendan_49: What is the combined valuation of the HIF-PH for CKD anemia space? $FGEN $3.5b cap, lets attribute $1b to cash + pamrev, so\xe2\x80\xa6'"
2020-12-30,"b""@brendan_49 $FGEN seems cheap, if you mock up some bull (clean label) vs bear cases; any reasonable split on probability makes them an interesting pickup for someone. \n\nThe fibrosis asset alone is quite intriguing.. \n\nI'd reckon once we're past the safety question, whatever the outcome.. +++"""
2020-12-30,"b'What is the combined valuation of the HIF-PH for CKD anemia space? $FGEN $3.5b cap, lets attribute $1b to cash + pamrev, so $2.5b roxa valuation. FGEN owns half the economics so roxa value is $5b. $AKBA $400m. Dapro? If roxa = $5b lets call dapro $1.5b. \n\nCombined= $7b https://t.co/MP4dT3fc0a'"
2020-12-30,b'RT @Bios_n_Techs: @semodough $KPTI $MYOV $MREO $ONCT $FGEN $TCON $PAVM $TRIL my top additional favs (apart from $OCUL $TGTX)'
2020-12-30,b'Calls held:\n12/31\n$SNAP $51\n1/15\n$AMZN $3500 $ARLO 10\n$BPY 20 $BYND 200\n$CNET 2 $DIS 190 $FGEN 60\n$FSLY 120 $GSKY 5 $MJ 20\n$MPLN 12.5 $PAYS 7.5\n$PFE 45 $PRTY 7.5 $SLV 30\n$SONO 30 $SPOT 350\n$TDOC 250 $TGT 200\n$TIF 135 $TSLA 700\n$WKHS 20 $WKHS 30\n$WMT 175\n1/22\n$ZM 410\n(1/3)'
2020-12-29,b'Looking forward to 2021 watching $ARWR $TPTX $CRIS $ONCT $ETON $FGEN $APLS $APTO $PHAS $KPTI $ALPN.'
2020-12-29,"b'Evening Most Tweeted Mid Caps, check out Gambiste Top 10: $ostk $ARCT $NNOX $PRPL $MSTR $FUTU $SGMO $OPK $FGEN https://t.co/k3uyuEbRpJ'"
2020-12-29,"b'$IFF, $IONS and $FGEN all in the Weinstein stage 1 setup phase according to our stock screener. https://t.co/QPBqOMq9hD'"
2020-12-29,"b""@musicandwork @oRx_93 @tuduylinh honestly, i don't care for your snide remark. the fact of the matter is that $FGEN is heading towards either black box label or CRL."""
2020-12-29,"b'@oRx_93 @tuduylinh i agree that $AKBA is not pristine. but I think once comparison of HIF vs standard of care is done for NDD patients is done, you will likely see elevated MACE risk beyond 11mg/dL of hemoglobin. i am frustrated that the $FGEN analysis was done against placebo.'"
2020-12-29,"b'@musicandwork @Harmbrit @JakeArman6 @tuduylinh Looks like vada was a clear fail by all accounts, and roxa has a fair chance of US approval according to cowen/jeff reports. $FGEN clearly in a much better position...'"
2020-12-29,b'@JakeArman6 @oRx_93 @tuduylinh Got to wonder the motive of people creating recent twitter accounts (with 0 followers) versus those who have a long lasting reputation going back years supporting $FGEN. Perhaps they just want to pump a bagholding position w/o tainting their regular biotwit account.'
2020-12-29,b'RT @JakeArman6: @oRx_93 @tuduylinh pardon me? $AKBA data is actually clear and consistent. $FGEN data is cherry picked and meant to pull th\xe2\x80\xa6'
2020-12-29,b'$fgen added another slug @ $38.50 here.'
2020-12-29,"b""@oRx_93 @tuduylinh pardon me? $AKBA data is actually clear and consistent. $FGEN data is cherry picked and meant to pull the wool over FDA's eyes for a quick buck, meanwhile killing CKD patients."""
2020-12-29,b'$FGEN Turn Green.. NOT Red... -3.76 %  https://t.co/8DpmJxbXgv'
2020-12-29,b'RT @salinaro17: $fgen clinical trials for Pamrevlumab now commence I China https://t.co/NpaXksyKqb'
2020-12-29,b'Calls held:\n1/15\n$AMZN $3500 $ARLO 10\n$BPY 20 $BYND 200\n$CNET 2 $DIS 190 $FGEN 60\n$FSLY 120 $GSKY 5 $MJ 20\n$MPLN 12.5 $PAYS 7.5\n$PFE 45 $PRTY 7.5 $SLV 30\n$SONO 30 $SPOT 350\n$SPY 373 $TDOC 250\n$TGT 200 $TIF 135\n$TSLA 700 $WKHS 20\n$WKHS 30 $WMT 175\n(1/3)'
2020-12-29,b'Interesting read about a seemingly overlooked HIF-PH inhibitor from $JAPAY approved in Japan for indications of CKD anemia. Going to have to look at how efficacy sizes up to the comp set! $FGEN $AKBA #pharma #biotech #healthcare\nhttps://t.co/eGK13sGlHD'
2020-12-29,"b'RT @oRx_93: @tuduylinh See where you\xe2\x80\x99re coming from (especially IO angle w/o validating data), but all the above have clinical data showing\xe2\x80\xa6'"
2020-12-29,"b'@tuduylinh See where you\xe2\x80\x99re coming from (especially IO angle w/o validating data), but all the above have clinical data showing that its \xe2\x80\x98in the running\xe2\x80\x99 for best in class. Two examples you\xe2\x80\x99ve given are tough - NASH market still a relative unknown, $AKBA CKD data sucks compared to $FGEN'"
2020-12-29,b'RT @salinaro17: $fgen clinical trials for Pamrevlumab now commence I China https://t.co/NpaXksyKqb'
2020-12-29,b'RT @salinaro17: $fgen clinical trials for Pamrevlumab now commence I China https://t.co/NpaXksyKqb'
2020-12-28,b'$fgen roxadustat now listed on https://t.co/lk834Aoj26 Is it biggest on line pharmacy network in China?Web site not best in translation but I see over 50 listings. Would seem natural for non dd https://t.co/MWF6UPFrEG'
2020-12-28,"b'@Biomaven @salinaro17 @Biomaven what is ur opinion on this drug? Have appreciated ur insight on $FGEN, but a lot of skeptics on whether they are a 1 drug deal'"
2020-12-28,"b""@oRx_93 $vktx vs $mdgl, $akba vs $fgen same type of benchnmark/logic didn't work put too well ( i can think of plenty other pairs in oncology IOs) i'm long $tril, the other ones on ur list i pass."""
2020-12-28,b'$fgen clinical trials for Pamrevlumab now commence I China https://t.co/NpaXksyKqb'
2020-12-28,b'$HNRG $FANG $GWB $XP $FSR $YEXT $FLUX $INSG $VRSN $GFN $FGEN $LUV $GWRE $JD $DADA $OZON $AAOI $VLDR $STIC $PGNY $ALGN $ADSK $BLDP $TDOC $SDGR $FNKO\n\nA few more interesting ones in the watchlist.'
2020-12-27,b'RT @ZSugar2019: @froggytrade $FGEN please! \xf0\x9f\x98\xac'
2020-12-27,b'@froggytrade $FGEN please! \xf0\x9f\x98\xac'
2020-12-27,"b'Really like $FGEN here. 3mo delay and chart is wound around the 40.2 level. If approval, it primes a move for &gt;$90'"
2020-12-27,b'RT @Bios_n_Techs: @semodough $KPTI $MYOV $MREO $ONCT $FGEN $TCON $PAVM $TRIL my top additional favs (apart from $OCUL $TGTX)'
2020-12-27,b'RT @Bios_n_Techs: @semodough $KPTI $MYOV $MREO $ONCT $FGEN $TCON $PAVM $TRIL my top additional favs (apart from $OCUL $TGTX)'
2020-12-27,b'@semodough $KPTI $MYOV $MREO $ONCT $FGEN $TCON $PAVM $TRIL my top additional favs (apart from $OCUL $TGTX)'
2021-01-08,b'$FGEN First Gen Corp. New 52-Week High'
2021-01-08,b'$APO 52WH .87 doing 1.03\n$FGEN 52WH 29.80 doing 30.25\n$PHA 52WH 1.47 doing 1.50'
2021-01-08,b'$FGEN - Brokeout of a base.  52-week high. Will observe price before closeout. https://t.co/v4xPgaCdLc'
2021-01-08,b'Bought $FGEN'
2021-01-07,b'@jmbiofarm @_B_I_O_T_E_C_H_ Both $FGEN and $PTCT are interesting in light of srpt results  IMO'
2021-01-07,b'@_B_I_O_T_E_C_H_ Just goes to show how hard it is to predict these results (or how crooked the sell side is). Probably a bit of both. No position. This failure makes me think $FGEN is more interesting'
2021-01-07,b'@sciencescanner $fgen at recent Jett foundation q and a. Question is about reduction of fibrosis https://t.co/zoVTvcaLgH'
2021-01-07,"b""@sciencescanner But it might still be possible to intervene some downstream - the (very preliminary) reports on the use of $FGEN's pamrevlumab in established (non-ambulatory) DMD to combat the associated fibrosis suggests some modest improvement is still possible."""
2021-01-07,b'@prosperousguy @HillScottW Not sure how I did that.  $FGEN PDUFA is 3/20.'
2021-01-07,b'RT @SnackBioTech: $XAIR $HZNP $ONCT trimming quite a bit. Leaving shares to help me keep track because I like them long term potentially. $\xe2\x80\xa6'
2021-01-07,"b'$XAIR $HZNP $ONCT trimming quite a bit. Leaving shares to help me keep track because I like them long term potentially. $BTAI $FGEN my laggards. $OMER thinking about running away, but the volume isn\xe2\x80\x99t quite there. Not sure what to make of it. Wouldn\xe2\x80\x99t be shocked by a pullback https://t.co/2xM5dtNgOE'"
2021-01-07,"b'While up 2$ per share, $FGEN still strikes us as a very attractive opportunity based on R/R.\n""Overall, we see significant upside potential with the potential approval of roxadustat in the EU and the US."" \n\nRead more in our report here:\nhttps://t.co/cp0TenaCzd\n\n$FGEN $AZN $ALPMY'"
2021-01-07,"b'RT @TomSilver39: Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks\xe2\x80\xa6'"
2021-01-07,"b'RT @TomSilver39: Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks\xe2\x80\xa6'"
2021-01-07,"b'RT @TomSilver39: Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks\xe2\x80\xa6'"
2021-01-07,"b""@brendan_49 So I fully expect they will get their clinical trial system improved too. I think they understand that credibility is important. Interestingly, $FGEN is opening around a dozen sites in China for pamrevlumab in IPF - let's see how enrollment goes."""
2021-01-07,"b""@brendan_49 Not that I can see yet. Their regulatory system is clearly modernizing, as is their reimbursement system. Look at $FGEN's roxadustat as a harbinger here - they approved much more quickly than the US and provided good and speedy national reimbursement. Patent system also improving"""
2021-01-07,"b'RT @TomSilver39: Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks\xe2\x80\xa6'"
2021-01-07,"b'Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks are : $ABBV, $ACAD, $ALKS, $KRTX and $AXSM .""'"
2021-01-07,"b'$FGEN FibroGen, Inc SEC Filing: Form SC 13G/A https://t.co/GXqECNLmNk'"
2021-01-07,b'$FGEN Primecap Management Co/Ca/ has filed Form SC 13G/A with SEC. Reporting 10.14% Ownership.\n\nhttps://t.co/t5CkFUZh7T'
2021-01-07,"b'$FGEN [15s. delayed] filed form SC 13G/A on January 07, 10:04:13 https://t.co/afcq5flmpq'"
2021-01-07,"b""$FGEN's 10-day Moving Average moved below its 50-day Moving Average on December 29, 2020. View odds for this and other indicators: https://t.co/1y29K8Nz1o #FibroGen #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/VJqs68KwkF"""
2021-01-07,"b'RT @BioSandyTrade: Cuurent Holdings  $CMRX, $CRBP, $CFMS, $IMMP, $PTGX, $AUPH, \n\n$BATI sold with 25% gain\n$BLU sold with decent gain\n$FGEN\xe2\x80\xa6'"
2021-01-07,b'Calls held:\n1/15\n$BPY $20 $CNET 2 $FGEN 60\n$GSKY 5 $MARA 18 $MJ 20\n$MPLN 12.5 $PAYS 7.5\n$SONO 30 $TDOC 250\n$TIF 135\n2/19\n$DM $25 $FCEL 15 $GAN 25\n$LAC 25 $MNKD 3 $PAAS 38\n$PRTS 10 $SNDL 1 $TIGR 10\n$TTCF 30 $VERU 10\n$WKHS 25\n3/19\n$COST $400 $NFLX 600\n$RBAC 12.5 $SSYS 17.5\n(1/2)'
2021-01-07,"b'All of our tickers for tomorrow, be careful it may be super red:\n\nhttps://t.co/Ww31MloBsJ\n\n$ALNY\n$ATNX\n$BAND\n$BILL\n$CDW\n$EBR\n$FGEN\n$PSA\n$SDC\n$SUI\n$VRSN'"
2021-01-07,"b'$FGEN FibroGen, Inc SEC Filing: Form 4 https://t.co/ufgY7y08Ab'"
2021-01-07,"b'$FGEN [15s. delayed] filed SEC form 4: Director Schoeneck James A: \nConverted securities 6,000 of Common Stock at price $9.78 on 2021-01-04, increased holding by 64% to 15,400 shares  https://t.co/NpsMZ8Jq0g'"
2021-01-06,"b""Rose Above Previous Day's High today: $CCO $KOS $JDIV $BTEC $SDEM $JCTCF $YSAC $GWRS $PBYI $ADPT $MTSI $SPNE $IBBJ $FGEN $INSM $BXMX $ADMP $RLY $LMRK $GRSVU ... https://t.co/TBYRpvrFqi"""
2021-01-06,"b""RT @ByJoFagg: While two #covid19 vaccines were granted EUAs last month there were still some big regulatory disappointments, here's my trac\xe2\x80\xa6"""
2021-01-06,"b""RT @ByJoFagg: While two #covid19 vaccines were granted EUAs last month there were still some big regulatory disappointments, here's my trac\xe2\x80\xa6"""
2021-01-06,"b""RT @ByJoFagg: While two #covid19 vaccines were granted EUAs last month there were still some big regulatory disappointments, here's my trac\xe2\x80\xa6"""
2021-01-06,"b""While two #covid19 vaccines were granted EUAs last month there were still some big regulatory disappointments, here's my tracker of #FDA\xf0\x9f\x91\x8d\xf0\x9f\x91\x8e $NVS $AZN $FGEN $BMY $BCRX $SCPH #Pdufa https://t.co/ocOtbRZrGq"""
2021-01-06,b'RT @MarcJacksonLA: $FGEN Dosing Begins In 2nd Phase 3 Trial Of Antibody Treatment For IPF https://t.co/9mIsnDVlja'
2021-01-06,b'RT @Frankie1x2: $FGEN\nArticle about Zephyrus in Pulmonary Fibrosis New\n\nhttps://t.co/sWjRRu3q5R'
2021-01-06,b'RT @Frankie1x2: $FGEN\nA new scientific article from a german university; Article is about research of cancer therapy with HIF inhibitors.\xe2\x80\xa6'
2021-01-06,b'$FGEN Dosing Begins In 2nd Phase 3 Trial Of Antibody Treatment For IPF https://t.co/9mIsnDVlja'
2021-01-06,b'$FGEN\nArticle about Zephyrus in Pulmonary Fibrosis New\n\nhttps://t.co/sWjRRu3q5R'
2021-01-06,"b'$FGEN\nA new scientific article from a german university; Article is about research of cancer therapy with HIF inhibitors.\n\nWays into Understanding HIF Inhibition\nArticle is from 1/5/2021\n(Link is not possible, just google the title)'"
2021-01-06,b'FibroGen - Late-Breaking Roxadustat Safety Results at Kidney Week 2020 https://t.co/BxgxzKwKIB via @YouTube $fgen'
